Lung BiopsyON-SITENCT07045103
A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
An observational study of Lung Biopsy and Lung Cancer, run by Invenio Imaging Inc. at 7 sites in United States.
Trial summary
The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging… Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Lung Biopsy, Lung Cancer, Lung Cancer (Diagnosis)
- How many people
- 1,006 participants
- Where
- 7 sitesUnited States
- Study dates
- 21 Dec 2023to 1 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who are scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion. Patients who meet criteria will be enrolled consecutively from 5 different Hospitals including MD Anderson Cancer Center, University of North Carolina Medical Center, Corewell Health, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of San Diego, Mayo Clinic
Who may be able to join
- The patient or legal guardian is willing and able to understand, sign and date the Ethics committee approved study specific Informed Consent Form.
- The patient is 22 years of age or older.
- The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion.
- The patient can tolerate the clinical procedure as indicated.
Who cannot join
- Patient is a prisoner.
- The participant, in the judgment of the Investigator, may be inappropriate for the intended study procedures
Trial locations and contacts
7 sites in 1 country.
7 sites in 1 country
United States7 sites
UNC Medical Center
Chapel Hill, North Carolina, 27514
Corewell Health
Grand Rapids, Michigan, 49503
MD Anderson Cancer Center
Houston, Texas, 77030
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
UC San Diego
San Diego, California, 92037
Montefiore Medical Center
The Bronx, New York, 10467
About this study
Official title: A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection
The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging System in the procedure room without requiring traditional sample processing.
The study includes four arms based on biopsy location and biopsy modality/tool:
- Transbronchial forceps biopsy of peripheral lung nodules/masses (peripheral-TBBx)
- Transbronchial needle aspiration biopsy of peripheral lung nodules/masses (peripheral TBNA)
- Transbronchial needle aspiration biopsy of mediastinal/hilar lymph nodes (EBUS-TBNA)
- Transbronchial cryo biopsy of peripheral lung nodules/masses (peripheral-CBx)
- Conditions
- Lung Biopsy, Lung Cancer, Lung Cancer (Diagnosis)
- Keywords
- lung cancer, AI, Bronchoscopy
- Medical subject headings
- Lung Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| ON-SITE Patients | Participants must fulfill all of the following criteria in order to be eligible for the study: 1. The patient or legal guardian is willing and able to understand, sign and date the Ethics committee-approved study specific Informed Consent Form. 2. The patient is 22 years of age or older. 3. The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral-TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion. 4. The patient can tolerate the clinical procedure as indicated. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peripheral TBBx and CBx Co-primary Endpoints
Detection of lung cancer in peripheral TBBx and CBx biopsies by NIO image analysis module with non-inferior performance compared to rapid on-site evaluation touch imprint cytology (ROSE-TIC)
Measured: From enrollment to the End of the Procedure.
Peripheral Lung Transbronchial Fine Needle Aspiration Endpoint
Detection of lung cancer in peripheral lung transbronchial needle aspiration by NIO image analysis module with non-inferior performance compared to rapid on-site evaluation (ROSE).
Measured: From enrollment to the End of the Procedure.
Lymph Node Endobronchial Ultrasound Transbronchial Fine Needle Aspiration Endpoint
Determine area-under-the-curve (AUC) of the receiver-operating-characteristic (ROC) of NIO image analysis module for detection of cancer at a lymph-node location.
Measured: From enrollment to the End of the Procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2025
- Study start21 Dec 2023
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung BiopsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 1,006 participants (actual)
Sponsor and investigators
- Lead sponsor
- Invenio Imaging Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Memorial Sloan Kettering Cancer Center, University of North Carolina, Chapel Hill, M.D. Anderson Cancer Center, Mayo Clinic, University of California, San Diego, Montefiore Medical Center-Moses-Weiler, Corewell Health, National Cancer Institute (NCI)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07045103
- Sponsor's protocol ID
- INV-01-2022
- Other IDs
- 1R44CA281581-01
- Acronym
- ON-SITE
- Status last verified
- Nov 2026
- First submitted
- 20 Jun 2025
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection
- ClinicalTrials.gov ID
- NCT07045103
- Acronym / sponsor ID
- ON-SITE / INV-01-2022
- Conditions
- Lung Biopsy, Lung Cancer, Lung Cancer (Diagnosis)
- Keywords
- lung cancer, AI, Bronchoscopy
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,006 participants (actual)
- Lead sponsor
- Invenio Imaging Inc.Industry (pharma, biotech, devices)
- Collaborators
- Memorial Sloan Kettering Cancer Center, University of North Carolina, Chapel Hill, M.D. Anderson Cancer Center, Mayo Clinic, University of California, San Diego, Montefiore Medical Center-Moses-Weiler, Corewell Health, National Cancer Institute (NCI)
- Study start
- 21 Dec 2023 (actual)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 1 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging System in the procedure room without requiring traditional sample processing.
The study includes four arms based on biopsy location and biopsy modality/tool:
- Transbronchial forceps biopsy of peripheral lung nodules/masses (peripheral-TBBx)
- Transbronchial needle aspiration biopsy of peripheral lung nodules/masses (peripheral TBNA)
- Transbronchial needle aspiration biopsy of mediastinal/hilar lymph nodes (EBUS-TBNA)
- Transbronchial cryo biopsy of peripheral lung nodules/masses (peripheral-CBx)
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ON-SITE Patients | – | –Participants must fulfill all of the following criteria in order to be eligible for the study: 1. The patient or legal guardian is willing and able to understand, sign and date the Ethics committee-approved study specific Informed Consent Form. 2. The patient is 22 years of age or older. 3. The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral-TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion. 4. The patient can tolerate the clinical procedure as indicated. |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who are scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion. Patients who meet criteria will be enrolled consecutively from 5 different Hospitals including MD Anderson Cancer Center, University of North Carolina Medical Center, Corewell Health, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, University of San Diego, Mayo Clinic
Key inclusion criteria (4 listed)
- The patient or legal guardian is willing and able to understand, sign and date the Ethics committee approved study specific Informed Consent Form.
- The patient is 22 years of age or older.
- The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion.
- The patient can tolerate the clinical procedure as indicated.
Key exclusion criteria (2 listed)
- Patient is a prisoner.
- The participant, in the judgment of the Investigator, may be inappropriate for the intended study procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Peripheral TBBx and CBx Co-primary Endpoints
Time frame: From enrollment to the End of the Procedure.
Detection of lung cancer in peripheral TBBx and CBx biopsies by NIO image analysis module with non-inferior performance compared to rapid on-site evaluation touch imprint cytology (ROSE-TIC)
Peripheral Lung Transbronchial Fine Needle Aspiration Endpoint
Time frame: From enrollment to the End of the Procedure.
Detection of lung cancer in peripheral lung transbronchial needle aspiration by NIO image analysis module with non-inferior performance compared to rapid on-site evaluation (ROSE).
Lymph Node Endobronchial Ultrasound Transbronchial Fine Needle Aspiration Endpoint
Time frame: From enrollment to the End of the Procedure.
Determine area-under-the-curve (AUC) of the receiver-operating-characteristic (ROC) of NIO image analysis module for detection of cancer at a lymph-node location.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Lung Biopsy
Active, not recruitingObservational study
Detection and Prediction of Clinically Significant Pneumothorax After Image-guided Transthoracic Lung Biopsy
Lung Biopsy
Not yet recruitingObservational study
Safety of Bronchoscopy in Patients With Interstitial Lung Disease
Interstitial Lung Disease (ILD), Bronchoscopy
Recruiting
Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease
Interstitial Lung Disease (ILD), Lung Biopsy
Not yet recruiting
The Percutaneous Interventional Surgery Control System for Pulmonary Nodule Biopsy
Pulmonary Nodules, Lung Cancer (Diagnosis)
Recruiting
Accuracy Between Transthoracal Needle Aspiration (TTNA) Techniques in Suspected Lung Cancer Patients
Lung Cancer (Diagnosis), Biopsy, Fine-Needle/Methods
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Biopsy and Lung Cancer, run by Invenio Imaging Inc. at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peripheral TBBx and CBx Co-primary Endpoints (time frame: From enrollment to the End of the Procedure.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.